Literature DB >> 11433883

Clonidine abuse among opiate addicts.

S J Dennison1.   

Abstract

OBJECTIVE: To determine if clonidine abuse among non-pregnant opiate dependent individuals is common and the reason for such use.
METHOD: Self report of personal use or knowledge of others' use of this drug.
RESULTS: Fourteen of fifteen treatment seeking individuals with opiate dependence knew of clonidine abuse. Ten had used it personally to decrease the amount of heroin necessary to achieve a desired effect and to prolong the length of the opiate's action.
CONCLUSION: Clonidine abuse among opiate addicts may be more common than previous studies have suggested. Opiate addicts should be screened for abuse of this substance, especially in view of its widespread use for the purpose of opiate withdrawal. Further, such patients should be warned of potential health hazards attendant upon clonidine use and abrupt cessation.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11433883     DOI: 10.1023/a:1010375727768

Source DB:  PubMed          Journal:  Psychiatr Q        ISSN: 0033-2720


  15 in total

1.  Evaluation of clonidine suppression of opiate withdrawal reactions: a multidisciplinary approach.

Authors:  J D Cuthill; V Beroniade; V A Salvatori; F Viguié
Journal:  Can J Psychiatry       Date:  1990-06       Impact factor: 4.356

2.  Enhancement of analgesic effect of intrathecal neostigmine and clonidine on bupivacaine spinal anesthesia.

Authors:  P M Pan; C T Huang; T T Wei; M S Mok
Journal:  Reg Anesth Pain Med       Date:  1998 Jan-Feb       Impact factor: 6.288

3.  Extradural analgesia with clonidine and fentanyl compared with 0.25% bupivacaine in the first stage of labour.

Authors:  D J Buggy; C MacDowell
Journal:  Br J Anaesth       Date:  1996-02       Impact factor: 9.166

4.  Noradrenergic hyperactivity in opiate withdrawal supported by clonidine reversal of opiate withdrawal.

Authors:  M S Gold; D E Redmond; H D Kleber
Journal:  Am J Psychiatry       Date:  1979-01       Impact factor: 18.112

Review 5.  Opiate detoxification protocols. A clinical manual.

Authors:  D A Fishbain; H L Rosomoff; R Cutler
Journal:  Ann Clin Psychiatry       Date:  1993-03       Impact factor: 1.567

6.  Clonidine hallucinations.

Authors:  M J Brown; D Salmon; M Rendell
Journal:  Ann Intern Med       Date:  1980-09       Impact factor: 25.391

7.  Extradural clonidine combined with sufentanil and 0.0625% bupivacaine for analgesia in labour.

Authors:  D Chassard; L Mathon; F Dailler; F Golfier; J P Tournadre; P Boulétreau
Journal:  Br J Anaesth       Date:  1996-10       Impact factor: 9.166

8.  Clonidine use and abuse among methadone program applicants and patients.

Authors:  M Beuger; A Tommasello; R Schwartz; M Clinton
Journal:  J Subst Abuse Treat       Date:  1998 Nov-Dec

9.  [Effects of clonidine on opiate withdrawal symptoms. Results - biochemical mechanisms (author's transl)].

Authors:  M Girard; M Escande; F Granier; J P Gardes
Journal:  Encephale       Date:  1982       Impact factor: 1.291

10.  Two cases of clonidine abuse/dependence in methadone-maintained patients.

Authors:  P Lauzon
Journal:  J Subst Abuse Treat       Date:  1992
View more
  3 in total

1.  Survey of noncontrolled medication misuse patterns.

Authors:  Amelia Slane; Sophie Robert; Christine Rarrick; Erin Weeda
Journal:  Ment Health Clin       Date:  2022-06-10

2.  Using ecological momentary assessment to examine the relationship between craving and affect with opioid use in a clinical trial of clonidine as an adjunct medication to buprenorphine treatment.

Authors:  William J Kowalczyk; Landhing M Moran; Jeremiah W Bertz; Karran A Phillips; Udi E Ghitza; Massoud Vahabzadeh; Jia-Ling Lin; David H Epstein; Kenzie L Preston
Journal:  Am J Drug Alcohol Abuse       Date:  2018-04-10       Impact factor: 3.829

3.  Combined abuse of clonidine and amitriptyline in a patient on buprenorphine maintenance treatment.

Authors:  J Paul Seale; Trent Dittmer; Erika J Sigman; Holly Clemons; J Aaron Johnson
Journal:  J Addict Med       Date:  2014 Nov-Dec       Impact factor: 3.702

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.